Loading...

Uscom Limited

UCM.AX•ASX
Healthcare
Medical - Devices
A$0.01
A$-0.00(-17.65%)

Uscom Limited (UCM.AX) Stock Overview

Explore Uscom Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap3.5M
P/E Ratio-1.01
EPS (TTM)$-0.01
ROE-0.96%
Fundamental Analysis

AI Price Forecasts

1 Week$0.02
1 Month$0.02
3 Months$0.02
1 Year Target$0.01

UCM.AX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Uscom Limited (UCM.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 40.22, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.01 and a market capitalization of 3.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

40.22RSI (14)
0.00MACD
57.73ADX
Revenue Growth
39.89%
↑ 39.89%
Profit Growth
A$-0.01
↑ 19.92%
EPS Growth
A$-0.01
↑ 20.81%
Operating Margin
-74.28%
↑ 17.56%
ROE
-95.61%
↑ 19.92%
Dividend Yield
0.00%
Analyst Recommendations data is not available for UCM.AXAnalyst Recommendations details for UCM.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company also provides the SpiroSonic AIR, a digital multipath ultrasonic spirometer with a viral disinfection system for the elimination of COVID and tuberculosis; and respiratory devices. It serves hospitals and other medical care locations through a network of distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.

CEO

Robert Allan Phillips AMS, DMU, FASE, FIR, MPhil (Med), Ph.D.(Med)

Employees

35

Headquarters

66 Clarence Street, Sydney, NSW

Founded

2003

Frequently Asked Questions

;